No internet connection — showing the saved version of the page.

IDEXX Laboratorie…

USUSD
← to the screener
US:IDXXLSE:0J8P

IDEXX Laboratories Inc (US:IDXX) — Biotechnology: In Vitro & In Vivo Diagnostic Substances. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
idexx.com
Investor relations
idexx.com/en/about-idexx/investors/
Sector
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances
Headquarters
Westbrook, United States
Management
Michael G. Erickson
  • Jonathan J. Mazelsky · Executive Chair of the Board, IDEXX Laboratories, Inc.
  • Sam Samad · Executive Vice President and Chief Financial Officer, Quest Diagnostics Incorporated
  • Andrew Emerson · Executive Vice President, Chief Financial Officer and Treasurer
  • Dr. Steve Hotchkiss · Owner and Chief Vision Officer
  • Amit Gupta · Senior Vice President and Chief Digital & Information Officer
  • Bob Asmann · Senior Vice President, Global Operations
  • Dan Janson · Senior Vice President and General Manager, Global Reference Laboratories
  • Eric Tracy · Senior Vice President, Customer Experience
  • Julie Godon · Senior Vice President and Global Marketing Officer
  • Tracy Byers · Senior Vice President, Veterinary Software, Diagnostic Imaging, and Telemedicine
Latest reports
quarterly 2025 · Earnings snapshotPDF
Employees
5 000
Founded
1983
IPO
1991-06-21
Shares outstanding
78.79 M as of 2026-10-28
DateSharesChange
28.10.202678.79 M—no significant change
31.07.202678.78 M
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
78.5 M
Market cap
45.38 B USD
Insiders
0.22%
Institutions
96.73%
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
Legal form
XTIQ
ISIN
US45168D1046
LEI
OGMTXK0LUU1HKV2P0J84
P/E
47.1
EPS
14.84 USD
|
29.1
Graham number
69.02 USD price 912% above
ROE
72.1%
FCF
1.30 B USD
Debt
849 M USD
0.5 y of FCF
Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
Net income
1.18 B USD 12 mo.
For the 12 months to 30.09.2026 (4 quarters)
Revenue4.66 B USD
− Expenses3.16 B USD
Gross profit2.92 B USD
Net income1.18 B USD
History by quarter
RevenueExpenses
31.12.2023: Revenue 902 M · Expenses 656 M · Operating profit 245 M · Net income 195 M31.03.2024: Revenue 964 M · Expenses 665 M · Operating profit 299 M · Net income 236 M30.06.2024: Revenue 1.00 B · Expenses 740 M · Operating profit 264 M · Net income 203 M30.09.2024: Revenue 976 M · Expenses 672 M · Operating profit 304 M · Net income 233 M31.12.2024: Revenue 954 M · Expenses 693 M · Operating profit 262 M · Net income 216 M31.03.2025: Revenue 998 M · Expenses 682 M · Operating profit 317 M · Net income 243 M30.06.2025: Revenue 1.11 B · Expenses 736 M · Operating profit 373 M · Net income 294 M30.09.2025: Revenue 1.11 B · Expenses 750 M · Operating profit 355 M · Net income 275 M31.12.2025: Revenue 1.09 B · Expenses 775 M · Operating profit 316 M · Net income 248 M31.03.2026: Revenue 1.14 B · Expenses 778 M · Operating profit 363 M · Net income 278 M30.06.2026: Revenue 1.22 B · Expenses 791 M · Operating profit 426 M · Net income 338 M30.09.2026: Revenue 1.21 B · Expenses 812 M · Operating profit 402 M · Net income 317 M
12.202309.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
23.72 USD · P/NAV 29.4
Balance sheet date30.09.2026
Assets3.71 B USD
− Liabilities1.84 B USD
= NAV (equity of the company's shareholders)1.87 B USD
− Goodwill641 M USD
− Intangible assets118 M USD
= Tangible NAV1.11 B USD
Shares78 790 000
NAV per share23.72 USD
Tangible NAV per share14.10 USD
Share price (IDXX)698.47 USD
P/NAV29.44
NAV history
Balance sheet dateNAVNAV per share
30.09.20261.87 B USD23.72 USD
30.06.20261.61 B USD20.44 USD
31.03.20261.56 B USD19.64 USD
31.12.20251.61 B USD20.14 USD
30.09.20251.56 B USD19.52 USD
30.06.20251.46 B USD18.20 USD
31.03.20251.45 B USD17.93 USD
31.12.20241.60 B USD19.55 USD
Description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
US USA StocksIDXX primaryUSD698.47 +1.19%common stock
LSE London Stock Exchange0J8P IOBUSD703.89 0.00%common stock
depositary receipt
SA B3 Sao PauloI1DX34BRL538.1 +0.00%depositary receipt

Price

Hover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
Blackrock Inc.10.37%8.17 M2026-06-30
Vanguard Capital Managem…6.54%5.15 M2026-06-30
Vanguard Portfolio Manag…4.95%3.9 M2026-06-30
State Street Corporation4.76%3.75 M2026-06-30
Invesco Ltd.4.58%3.61 M2026-06-30
Geode Capital Management…3.25%2.56 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.18%2.5 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%2.04 M2026-06-30
BAMCO Inc.2.51%1.98 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.17%1.71 M2026-06-30
Invesco QQQ Trust, Serie…2.15%1.7 M2026-08-31
Morgan Stanley1.72%1.36 M2026-06-30
Bank Of New York Mellon…1.51%1.19 M2026-06-30
Arrowstreet Capital, Lim…1.35%1.07 M2026-06-30
iShares Trust-iShares Co…1.33%1.05 M2026-08-31
Fidelity Concord Street…1.29%1.02 M2026-07-31
SPDR S&P 500 ETF TRUST-S…1.23%966 4252026-08-31
VANGUARD INDEX FUNDS-Van…1.2%942 2892026-06-30
BARON SELECT FUNDS-Baron…1.07%846 3002026-06-30
Amcap Fund0.93%732 8612026-06-30
MAZELSKY JONATHAN JAY (C…≈0.11%83 8032026-02-27
MCKEON BRIAN P (Chief Fi…≈0.06%49 5992025-02-14
HUNT NIMRATA K (Officer)≈0.02%18 3002026-03-03
ERICKSON MICHAEL G (Offi…≈0.02%15 0922026-02-19
FENNELL GEORGE (Officer)≈0.01%10 4332026-06-01
KINGSLEY LAWRENCE D (Dir…≈0.01%9 5682026-09-04
VANDEBROEK SOPHIE V (Dir…≈0.01%9 0782026-05-07
LANE MICHAEL J (Officer)≈0.01%8 6152026-02-13
UNDERBERG SHARON E (Gene…≈0.01%7 1372026-03-03
EMERSON ANDREW (Chief Fi…≈0.01%4 4212026-08-20